Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

About Atara Biotherapeutics

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ATRA
  • CUSIP:
Key Metrics:
  • Previous Close: $13.60
  • 50 Day Moving Average: $18.54
  • 200 Day Moving Average: $19.94
  • 52-Week Range: $13.31 - $40.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.71
  • P/E Growth: 0.00
  • Market Cap: $391.83M
  • Outstanding Shares: 28,811,000
  • Beta: 0.73
  • Return on Equity: -22.03%
  • Return on Assets: -21.41%
  • Current Ratio: 29.89%
  • Quick Ratio: 29.89%
Additional Links:
Companies Related to Atara Biotherapeutics:

Analyst Ratings

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (?)
Ratings Breakdown: 2 Sell Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $27.33 (100.24% upside)

Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateFirmActionRatingPrice TargetDetails
10/24/2016Jefferies GroupInitiated CoverageBuy$25.00 -> $23.00View Rating Details
9/15/2016Goldman Sachs Group Inc.DowngradeNeutral -> Sell$23.00 -> $16.00View Rating Details
8/19/2016Citigroup Inc.Boost Price TargetSell$8.00 -> $10.00View Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 -> $34.00View Rating Details
12/15/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
11/5/2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.43)ViewN/AView Earnings Details
2/26/2015($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
Current Year EPS Consensus Estimate: $-2.86 EPS
Next Year EPS Consensus Estimate: $-3.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.68)($0.68)($0.68)
Q2 20161($0.65)($0.65)($0.65)
Q3 20162($0.80)($0.77)($0.79)
Q4 20162($0.90)($0.90)($0.90)
Q1 20171($0.87)($0.87)($0.87)
Q2 20171($0.88)($0.88)($0.88)
Q3 20171($0.89)($0.89)($0.89)
Q4 20171($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)


Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Ownership Percentage: 16.10%
Institutional Ownership Percentage: 75.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.00View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
DateHeadline logoWhat Falling Estimates & Price Mean for Atara Biotherapeutics (ATRA) (NASDAQ:ATRA) - October 27 at 3:52 PM
News IconSell-side Consensus Sees Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Going Where Near-Term? - CSZ News (NASDAQ:ATRA) - October 27 at 8:05 AM
News IconRating Flow: Atara Biotherapeutics (NASDAQ:ATRA) "Buy" Rating Reiterated at Jefferies & Co - Thorold News (NASDAQ:ATRA) - October 25 at 3:40 PM
News IconAtara Biotherapeutics Inc. (ATRA) stock starts with "Buy" rating in research note to investors by Jefferies Group - BNB Daily (blog) (NASDAQ:ATRA) - October 25 at 3:40 PM
News IconRating Sentiment of The Day: Are Analysts Bullish about Atara Biotherapeutics Inc (NASDAQ:ATRA) after last week? - MoneyMakingArticles (NASDAQ:ATRA) - October 21 at 3:38 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - CSZ News (NASDAQ:ATRA) - October 19 at 8:29 AM logoATARA Biotherapeutics (ATRA) Granted Access to CHMP, CAT PRIME Regulatory Imitative (NASDAQ:ATRA) - October 18 at 3:38 PM logoAtara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) (NASDAQ:ATRA) - October 18 at 8:28 AM
News IconNew Analyst Ratings On Atara Biotherapeutics, Inc. (NASDAQ:ATRA ... - NewsDen (NASDAQ:ATRA) - October 16 at 3:36 PM
News IconAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Updated Broker Price Targets - The De Soto Edge (NASDAQ:ATRA) - October 16 at 8:26 AM
News IconShare Value Diminishing Over Past Month: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - CSZ News (NASDAQ:ATRA) - October 16 at 8:26 AM
News IconInsider Filing On Watch: Atara Biotherapeutics Inc (NASDAQ:ATRA)'s Chief Financial Officer John Mcgrath Unloaded ... - Thorold News (NASDAQ:ATRA) - October 13 at 8:34 PM logoAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Sell Calls At 0 - Investor Newswire (NASDAQ:ATRA) - October 12 at 8:00 AM logoATARA Biotherapeutics (ATRA) Receives Positive EMA Opinion on ... - (NASDAQ:ATRA) - October 11 at 3:43 PM logoAtara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems (NASDAQ:ATRA) - October 11 at 3:43 PM
News IconStock Ballooning in Midday Session: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - CSZ News (NASDAQ:ATRA) - October 10 at 3:36 PM
News IconLatest Analyst Ratings For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - The De Soto Edge (NASDAQ:ATRA) - October 9 at 8:23 AM
News IconAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Updated Broker Ratings - NewsDen (NASDAQ:ATRA) - October 5 at 3:21 PM
News IconInsider Trading Update: Atara Biotherapeutics (ATRA) - The Voice Registrar (NASDAQ:ATRA) - October 3 at 8:25 AM logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ATRA) - September 24 at 8:57 AM
News IconWhat is the Street Saying About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)? - Frisco Fastball (NASDAQ:ATRA) - September 20 at 3:37 PM
News IconBrokerages Expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to ... - DailyQuint (NASDAQ:ATRA) - September 18 at 3:35 PM logoHealthcare ratings roundup - upgrades/downgrades (NASDAQ:ATRA) - September 16 at 12:23 PM logoAtara Biotherapeutics Has 25% Downside - Benzinga (NASDAQ:ATRA) - September 15 at 12:34 PM logoAtara Biotherapeutics downgraded by Goldman (NASDAQ:ATRA) - September 15 at 12:34 PM logoAtara Biotherapeutics Has 25% Downside (NASDAQ:ATRA) - September 15 at 12:34 PM logoCan Shares Of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Hit $25 - Investor Newswire (NASDAQ:ATRA) - September 14 at 7:22 AM logoAtara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:ATRA) - September 13 at 3:40 PM logoAtara Bio to Participate in the Morgan Stanley Global Healthcare Conference (NASDAQ:ATRA) - September 9 at 8:25 AM
News IconPlacing Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Under the Microscope - Post News (NASDAQ:ATRA) - September 8 at 3:34 PM
News IconStock in Review: Taking a Closer Look at Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares - Post News (NASDAQ:ATRA) - September 1 at 3:37 PM
News IconInsider Trading Review: Atara Biotherapeutics Inc (ATRA) - The Voice Registrar (NASDAQ:ATRA) - August 25 at 8:27 AM logoAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ATRA) - August 24 at 3:39 PM logoAtara Biotherapeutics, Inc. (ATRA) – Citigroup Holds Rating And ... - Finance Daily (NASDAQ:ATRA) - August 22 at 3:40 PM
News IconHow Analysts & Retail Investors Perceive Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Post News (NASDAQ:ATRA) - August 20 at 8:40 AM
News IconAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares in Focus According to the Crowd & Analysts - Post News (NASDAQ:ATRA) - August 18 at 3:47 PM logoInsider Activity - Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Finance Daily (NASDAQ:ATRA) - August 17 at 9:05 PM logoWill Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Hit $25 Price Target? - Investor Newswire (NASDAQ:ATRA) - August 17 at 3:42 PM logoATARA BIOTHERAPEUTICS, INC. Financials (NASDAQ:ATRA) - August 16 at 3:45 PM logoState Street Corp Increases Its Ownership in Atara Biotherapeutics, Inc. (ATRA) Last Quarter - Finance Daily (NASDAQ:ATRA) - August 12 at 9:05 PM logoTeachers Advisors Inc Adjusts Its Position in Atara Biotherapeutics, Inc. (ATRA) Last Quarter - Finance Daily (NASDAQ:ATRA) - August 11 at 9:33 PM logo5 Stocks Under Wall Street's Radar: Atara Biotherapeutics (NASDAQ:ATRA), Rite Aid (NYSE:RAD), EP Energy ... - KC Register (NASDAQ:ATRA) - August 10 at 4:00 PM logoWhy Need to Watch: Atara Biotherapeutics (NASDAQ:ATRA), QUALCOMM, Inc. (NASDAQ:QCOM), Westwood ... - KC Register (NASDAQ:ATRA) - August 9 at 12:27 PM logoAtara Biotherapeutics Inc.: Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights (NASDAQ:ATRA) - August 8 at 3:40 PM logoAtara Biotherapeutics : reports 2Q loss (NASDAQ:ATRA) - August 8 at 3:40 PM logoAtara Biotherapeutics reports 2Q loss - Yahoo Finance (NASDAQ:ATRA) - August 8 at 8:26 AM logoAtara Biotherapeutics reports 2Q loss (NASDAQ:ATRA) - August 8 at 8:26 AM logoAtara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights (NASDAQ:ATRA) - August 8 at 8:26 AM logoAtara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:ATRA) - August 4 at 9:24 PM
News IconInsider Trading to Watch for: Atara Biotherapeutics Inc (NASDAQ:ATRA) - The Voice Registrar (NASDAQ:ATRA) - July 28 at 12:23 PM


Atara Biotherapeutics (NASDAQ:ATRA) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff